Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · The Journal of Pediatrics · 2006
Cited by 364 works. doi:10.1016/j.jpeds.2005.12.014
Authors
- Paul Harmatz
- Roberto Giugliani
- Ida Vanessa Döederlein Schwartz
- Nathalie Guffon
- Elisa Leão Teles
- Clara Sá-Miranda
- James Edmond Wraith
- Michael Beck
- Laila Arash
- Maurizio Scarpa
- Zi‐Fan Yu
- Janet Turk Wittes
- Kenneth I. Berger
- Mary S. Newman
- Ann M. Lowe
- Emil Kakkis
- Stuart J. Swiedler
References
- The Metabolic Basis of Inherited Disease.
- Standardization of Spirometry, 1994 Update. American Thoracic Society
- ATS Statement: Guidelines for the Six-Minute Walk Test
- Interpreting Small Differences in Functional Status: The Six Minute Walk Test in Chronic Lung Disease Patients
- Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing
- Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators
- Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)
- The Metabolic Basis of Inherited Disease
- Bone-Marrow Transplantation in the Maroteaux–Lamy Syndrome (Mucopolysaccharidosis Type VI)